Andros Pharmaceuticals Co.,Ltd (6917.TWO)
Taipei Exchange · TWD · Healthcare · Biotechnology
NT$32.00 (+0.00%) as of
Key statistics
- Market cap
- 1.96B
- EPS (TTM)
- -0.63
- Dividend yield
- 0.00%
- 52-week range
- 18.40 – 45.95
- Profit margin
- 0.00%
- Volume
- 243.30k
About Andros Pharmaceuticals Co.,Ltd
Andros Pharmaceuticals Co.,Ltd, a biopharmaceutical company, engages in developing novel drug delivery platform technologies. The company develops APC101, a fast-drying, film-forming, and meter-dosed spray, which is in Phase IIa clinical trial to treat pain associated with post-herpetic neuralgia; APC201, a novel dosage form of topical anesthetic that is in Phase I/II clinical trial for treatment of Osteoarthritis; and siRNA, an anti-sense oligonucleotide and DNA candidate. Its preclinical phase products are APC310 and APC501 for anesthesia to intravenous catheter placement and venipuncture; and APC401, a special emulsified solution for anesthesia of post-surgery pain. The company offers LALP cream for dermal analgesic applications; iMinos solution for Alopecia Androgenetica; and T4 endonuclease V. Andros Pharmaceuticals Co.,Ltd was founded in 2008 and is based in Zhubei, Taiwan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Zhubei, Taiwan
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.